4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
Revenue of 4D Molecular Therapeutics, Inc. (FDMT)
Revenue in 2023 (TTM): $20.72 M
According to 4D Molecular Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $20.72 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of 4D Molecular Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $20.72 M | $-76,373,000 | $-107,118,000 | $-100,837,000 | $-100,837,000 |
| 2022 | $3.13 M | $-751,000 | $-106,152,000 | $-107,494,000 | $-101,076,000 |
| 2021 | $18.04 M | $15.02 M | $-68,313,000 | $-71,317,000 | $-68,297,000 |
| 2020 | $13.61 M | $-39,426,000 | $-55,221,000 | $-56,693,000 | $-56,541,000 |
| 2019 | $6.99 M | $-31,732,000 | $-44,623,000 | $-49,306,000 | $-52,939,000 |
| 2018 | $14.13 M | $-4,232,000 | $-9,702,000 | $-9,551,000 | $-9,551,000 |
| 2017 | $5.79 M | $-7,783,000 | $-10,646,000 | $-11,223,000 | $-11,223,000 |